Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin's Stumble Again At NICE Underscores Importance Of Overall Survival Data

This article was originally published in The Pink Sheet Daily

Executive Summary

NICE rejection of Roche's Avastin comes a week ahead of target dates for U.S. and EU decisions on possibly withdrawing the indication, but still offers instructive lessons for working with technology assessment groups.

You may also be interested in...



Spurned By NICE On Avastin In Bowel Cancer, Roche Looks To U.K. Cancer Drugs Fund

NICE's definitive decision against Avastin in bowel cancer forces Roche to turn to Cancer Drugs Fund.

Spurned By NICE On Avastin In Bowel Cancer, Roche Looks To U.K. Cancer Drugs Fund

NICE's definitive decision against Avastin in bowel cancer forces Roche to turn to Cancer Drugs Fund.

NICE Likely To Lose Cost-Watchdog Status By 2013

A new value-based pricing system will make NICE's cost-assessment role redundant, say U.K. ministers.

Topics

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel